EVAX Evaxion Biotech A/S ADRs

Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus) induced skin and soft tissue infections. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$7.04  -0.37 (-4.99%)
As of 02/26/2021 13:39:35 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
ADRs
Micro cap
Health Care
Biotechnology
Denmark

02/04/2021
2,750,000
214,992
$19,195,000
0.00%
SEC Edgar Online
20-F



Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
2.45
0.00
-44.53%
0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy